Surgically Targeted Radiation Therapy (STaRT) for patients with operable brain tumors

Placed by a neurosurgeon at the time of resection, GammaTile Therapy gives patients a head STaRT in the fight against brain tumors, delaying tumor recurrence and potentially extending survival[1]

Limits radiation exposure to healthy tissue, minimizing side effects, including hair loss[2]

Assures 100% treatment compliance for all patients

Reduces patient and caregiver treatment burden in terms of time and travel

How does GammaTile Therapy work?

View our GammaTile Therapy animation.

Are you a clinician interested in GammaTile Therapy?

We can answer questions or schedule therapy training.

REFERENCES

1. Nakaji P, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.

2. Brachman D, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.

GammaTile® is indicated as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. For full product and safety information, refer to the Instructions for Use.